Browse studies

Find your next paid study

9 recruiting studies matching your filters

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negat…

Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaMetastatic Breast Carcinoma+1 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT04305834

Phase 1

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy …

Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+5 more

Estimated

~$10 – $7,500

BeOne MedicinesNCT06120283

Phase 1

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

This study is open to women who have early-stage breast cancer and are on aromatase inhibitor (AI) therapy, and who have hypoactive sexual desire disorder (HSD…

Early-stage Breast CancerHypoactive Sexual Desire DisorderHormone Receptor Positive Breast Carcinoma+1 more

Estimated

~$10 – $6,250

University of Illinois at ChicagoNCT07596212

Observational

Evaluating Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors

The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA …

Hormone Receptor Positive Breast CarcinomaPostmenopausalBreast Cancer

Estimated

~$10 – $6,250

Thomas Jefferson UniversityNCT07737951

Phase 1

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients …

Vulvar AdenocarcinomaPDAC - Pancreatic Ductal AdenocarcinomaGastric Adenocarcinoma+6 more

Estimated

~$10 – $8,750

Avacta Life Sciences LtdNCT07454642

Phase 2

Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788…

HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more

Estimated

~$10 – $7,500

Laura Huppert, MD, BANCT06224673

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used f…

HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more

Estimated

~$10 – $750

Mayo ClinicNCT06388122

Phase 2

A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting

This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone rec…

Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT04553770

Phase 4

Evaluation of Revaree Plus in Women With Breast Cancer

The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness du…

Breast CancerStage 0 Breast CancerStage I Breast Cancer+8 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07042581